Home » Newsletters » BioWorld Science

BioWorld Science

June 9, 2016

View Archived Issues

Enumeral and Pieris sign definitive license agreement

First clinical data reported for anti-CD47 monoclonal antibody Hu5F9-G4

Novartis initiates phase II trial of CLR-325 in chronic stable heart failure

Millendo Therapeutics begins phase II trial on ATR-101

Enanta Pharmaceuticals patents FXR agonists

European Commission approves Avastin plus Tarceva for advanced NSCLC with EGFR-activating mutations

Mochida Pharmaceutical discloses OX2 receptor antagonists

Oncothyreon changes name to Cascadian Therapeutics

Crispr Therapeutics and Anagenesis Biotechnologies enter collaboration for P2MC technology

Merck Patent presents IRAK inhibitors

Phase II trial of erenumab in chronic migraine prevention meets primary endpoint

Fibrocell Science reports negative results for phase II trial evaluating Azficel-T

Korea Institute of Science and Technology reports development of protein kinase inhibitors

Bayer Schering Pharma describes IRAK-4 inhibitors

FDA advisory committees recommend approval of Pfizer's ALO-02

Phase I results of BI-860585 for the treatment of solid tumors

Regorafenib administered to pediatric patients with solid tumors in phase I study

Update of clinical trials for cancer vaccine NY-ESO-1(c259) SPEAR T cells given at ASCO

FDA grants fast track designation to Remedy's Cirara

Theravance Biopharma and Takeda Pharmaceutical enter agreement for TD-8954

Galderma advances trifarotene program for lamellar ichthyosis

Ultragenyx and Takeda enter partnership to develop and commercialize rare genetic disease therapies

European Commission grants orphan drug designation to XLRP gene therapy candidate

PuriCore holds pre-IND meeting with FDA for PR-022 in atopic dermatitis

Activin-A inhibitor shows promise for the treatment of granulosa cell ovarian cancer

Aspen gains ex-U.S. commercialization rights to AstraZeneca's anesthetic portfolio

Phase III data for first expected trastuzumab biosimilar MYL-1401O

Capmatinib-gefitinib combination shows promise in EGFR-mutant/c-Met+ non-small cell lung cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...